Short-term (8 h for 5 days) or long-term infusion (LTI; continuous infusion over 10 days) of DB with or without subcutaneous IL-2 (scIL-2) improved survival in the first-line maintenance setting (HR-NBL1/SIOPEN study) [1,2,8] as well as in patients with relapsed and refractory neuroblastoma (LTI/SIOPEN study) [9,10]. The gene discussed is IL2; the disease is neuroblastoma.